Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Equities researchers at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Nuvation Bio in a note issued to investors on Tuesday, March 3rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.13) for the quarter, down from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.44) EPS.

Other equities research analysts have also recently issued research reports about the company. Royal Bank Of Canada upped their price target on Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday. Citizens Jmp set a $10.00 price objective on shares of Nuvation Bio in a research report on Thursday, November 20th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a report on Tuesday, February 10th. B. Riley Financial assumed coverage on shares of Nuvation Bio in a research note on Wednesday, November 19th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nuvation Bio has an average rating of “Moderate Buy” and a consensus price target of $11.44.

Nuvation Bio Stock Up 8.7%

Nuvation Bio stock opened at $4.74 on Thursday. The stock has a 50 day moving average of $6.45 and a two-hundred day moving average of $5.53. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $9.75. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -7.90 and a beta of 1.50. The company has a current ratio of 6.95, a quick ratio of 8.39 and a debt-to-equity ratio of 0.15.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). The firm had revenue of $41.87 million for the quarter, compared to analyst estimates of $36.82 million. Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NUVB. Los Angeles Capital Management LLC purchased a new stake in shares of Nuvation Bio during the 2nd quarter worth about $207,000. Tema Etfs LLC acquired a new position in Nuvation Bio during the second quarter valued at approximately $272,000. Aisling Capital Management LP lifted its position in Nuvation Bio by 16.5% during the third quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock valued at $10,954,000 after buying an additional 419,650 shares in the last quarter. Geode Capital Management LLC grew its stake in Nuvation Bio by 16.8% during the second quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock worth $11,691,000 after buying an additional 864,194 shares during the period. Finally, CWM LLC increased its position in shares of Nuvation Bio by 169.5% in the third quarter. CWM LLC now owns 102,328 shares of the company’s stock worth $379,000 after acquiring an additional 64,365 shares in the last quarter. 61.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $13 and kept an Outperform stance, providing a near-term bullish analyst endorsement that supports upside expectations. RBC Boosts NUVB Price Target
• Positive Sentiment: Nuvation announced it is transitioning to the commercial stage with progress on Iptrozi and safusidenib, a fundamental milestone that can lift revenue visibility and long-term valuation if launches and uptake go as planned. Nuvation Transitions To Commercial Stage
• Neutral Sentiment: H.C. Wainwright reiterated a Buy rating and a $17 price objective, signaling continued long?term confidence from that shop despite other adjustments. H.C. Wainwright Sticks to Buy
• Negative Sentiment: H.C. Wainwright sharply lowered its EPS forecasts for Q1–Q4 and cut FY2026 to ($0.44) from ($0.35), signaling weaker near?term profitability expectations that can pressure the stock despite the maintained Buy rating. HC Wainwright EPS Cuts
• Negative Sentiment: UBS trimmed its price target (from $10 to $7) and flagged lower expectations, reducing a key source of analyst support and likely weighing on sentiment. UBS Lowers Expectations
• Negative Sentiment: Johnson Fistel has opened an investor investigation into potential securities-law claims against Nuvation and its officers, introducing legal/settlement risk and additional uncertainty for investors. Johnson Fistel Investigation
• Negative Sentiment: Analyst commentary (TipRanks) highlights new commercialization and partner?execution risks for taletrectinib, underscoring operational challenges that could hinder product rollouts and revenue. Taletrectinib Commercialization Risk

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.